GlassScriptPhysician profile
Eric Jeffrey Raab
NPI 1184080509
$12,744.11
in general payments reported to CMS, 2019-2025
24 companies · $4,129 in 2025
The $4,129 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,052 · 2023: $2,604 · 2024: $3,960 · 2025: $4,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,551.89 |
| Education | $140.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,537.37 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,368.41 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,305.62 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,031.09 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $976.43 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $711.67 | 2024-2025 | Auvelity, Sunosi |
| Corium, LLC | $599.46 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $579.84 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $573.62 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $506.81 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $503.47 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $493.69 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $480.38 | 2022-2025 | Ingrezza |
| Almatica Pharma LLC | $439.75 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $313.95 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $296.98 | 2023-2025 | Dyanavel Xr, Quillichew Er, Onyda Xr |
| Neuronetics, INC. | $222.74 | 2022 | |
| Collegium Pharmaceutical, INC. | $204.81 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $188.56 | 2022 | |
| Tempus Ai, INC | $154.74 | 2024 | |
| Idorsia Pharmaceuticals US INC | $137.45 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $54.58 | 2022-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $35.86 | 2022 | |
| Indivior INC. | $26.83 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Raab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.